Kjeld Madsen

This inventor holds 19 USPTO granted patents and 9 published patent applications and 12 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 1998-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kjeld Madsen. Retrieved from https://idiyas.com/inventor/kjeld-madsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 9)

% Patents Active = 52.6

EPO Patents = 12 (Patent Applications = 7)

Average Co-Inventor Count = 6.3

ph-index = 12

Forward Citations = 585(Granted Patents)

Location History:

V.ae butted.rL.o slashed.se, DK (1998)
DK-3500 V.ae butted.rl.o slashed.se, DK (1999)
Vaerlose, DK (1999 - 2015)
Værløse, DK (2001 - 2015)
Videbaek, DK (2017)
Vaerloese, DK (1999 - 2018)

Company Filing History:

19 out of 1,802

Novo Nordisk A/s

patents

Years Active: 1998-2018

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9920106 - GLP-1 compounds (2018-03-20),

2. 9657079 - Truncated GLP-1 derivatives and their therapeutical use (2017-05-23),

3. 9061067 - Polypeptide protracting tags (2015-06-23),

4. 9012398 - Acylated exendin-4 compounds (2015-04-21),

5. 8097698 - Derivatives of GLP-1 analogs (2012-01-17),

6. 7541430 - Peptides for use in treating obesity (2009-06-02),

7. 7517854 - Melanocortin receptor agonists (2009-04-14),

8. 7411039 - GLP-2 compounds, formulations, and uses thereof (2008-08-12),

9. 7226990 - Extendin derivatives (2007-06-05),

10. 6939880 - Compounds with growth hormone releasing properties (2005-09-06),

11. 6555570 - Compounds with growth hormone releasing properties (2003-04-29),

12. 6268343 - Derivatives of GLP-1 analogs (2001-07-31),

13. 6127391 - Compounds with growth hormone releasing properties (2000-10-03),

14. 6127341 - Compounds with growth hormone releasing properties (2000-10-03),

15. 5998375 - Nociceptin analogues (1999-12-07),

Title: The Innovative Journey of Kjeld Madsen: Pioneering GLP-1 Compounds

Introduction:

Kjeld Madsen, a prolific inventor hailing from Vaerlose, Denmark, has significantly contributed to the field of pharmaceuticals with his groundbreaking work. With an impressive portfolio of 19 patents, his latest inventions in the realm of GLP-1 compounds showcase his relentless pursuit of innovation and therapeutic advancements.

Latest Patents:

Madsen's recent patents include the development of novel GLP-1 compounds and truncated GLP-1 derivatives, aimed at revolutionizing therapeutic approaches. These compounds exhibit enhanced potency, excellent binding affinity to the GLP-1 receptor, and the potential for once-weekly administration, marking a significant leap forward in the treatment of various medical conditions.

Career Highlights:

Currently affiliated with Novo Nordisk A/S, a leading pharmaceutical company at the forefront of diabetes care, Madsen's expertise and visionary approach have played a pivotal role in shaping the company's research and development endeavors. His contributions have not only elevated the company's scientific stature but have also paved the way for transformative advancements in the healthcare industry.

Collaborations:

In his innovative pursuits, Madsen has had the privilege of collaborating with accomplished individuals in the field, such as Thomas Kruse Hansen and Jesper F Lau. These partnerships have fostered a culture of innovation, knowledge exchange, and collective drive towards excellence, resulting in the successful development of pioneering pharmaceutical solutions.

Conclusion:

Kjeld Madsen's remarkable journey as an inventor exemplifies dedication, ingenuity, and a relentless pursuit of scientific excellence. His pioneering work in the realm of GLP-1 compounds has not only redefined therapeutic possibilities but has also set new benchmarks for innovation in pharmaceutical research. As he continues to push boundaries and explore new frontiers, Madsen's contributions are poised to shape the future of healthcare and inspire generations of aspiring inventors.

Profile summary based on public USPTO records.